Form 4: NextCure COO Timothy Mayer Granted Stock Options

NextCure, Inc. Chief Operating Officer Timothy Mayer was granted 14,670 employee stock options with an exercise price of $10.85.

Summary

• Timothy Mayer, Chief Operating Officer of NextCure, Inc. (NXTC), was granted 14,670 employee stock options.
• The options have an exercise price of $10.85 per share.
• The transaction date for this grant was January 30, 2026.
• One-fourth of the option vests on January 30, 2027.
• The remaining portion of the option vests in 36 equal monthly installments, commencing on February 28, 2027.
• The expiration date for these options is January 29, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine executive compensation action that aligns management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the Chief Operating Officer's long-term incentives with shareholder value creation.
• The vesting schedule encourages long-term commitment and performance from a key executive.

Negatives

• The exercise of these options in the future could result in minor dilution for existing shareholders.

Future Outlook

The filing details a standard vesting schedule for employee stock options, indicating a long-term incentive structure for the Chief Operating Officer, with vesting extending through January 2027 and monthly installments thereafter.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Operating Officer is a common practice in the biotechnology and pharmaceutical industries, including companies like NextCure, Inc. This strategy is widely used to attract, retain, and motivate talent by linking executive compensation to the company's long-term stock performance, thereby aligning management interests with those of shareholders. The specific terms, such as the exercise price and vesting schedule, are typical for such incentive plans.

Comparison to Industry Standards

• The grant of 14,670 options to a COO is a standard form of executive compensation, comparable to practices at similar-sized biotech firms.
• The exercise price of $10.85, likely the market price on the grant date, is typical for at-the-money option grants.
• A vesting schedule with an initial cliff (one-fourth after one year) followed by monthly installments over three years is a common structure designed to promote long-term executive retention and performance, mirroring plans seen at companies such as BioNTech or Moderna for their senior leadership.

Related Party Transactions

• The transaction involves an employee stock option grant to Timothy Mayer, the Chief Operating Officer, who is considered a related party to NextCure, Inc.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon exercise of options, but also potential benefit from aligned executive incentives.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a company executive and does not provide sufficient information to alter an investment thesis. It is a standard compensation event that aligns executive interests with shareholders but does not reflect new operational performance or strategic shifts that would warrant a change in recommendation based solely on this disclosure.

Keywords

NextCure, NXTC, Stock Options, Insider Transaction, Executive Compensation, Form 4, Timothy Mayer, Chief Operating Officer